New User:

Forgot your password?

Stock Market & Financial Investment News

News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 12, 2015
08:08 EDTLLYEli Lilly to discontinue development of Evacetrapib due to insufficient efficacy
Subscribe for More Information
08:06 EDTLLYEsperion jumps after Lilly ends evacetrapib development
Eli Lilly (LLY) said it will discontinue development of evacetrapib for the treatment of high-risk atherosclerotic cardiovascular disease and will now conclude other studies in the program after an independent data monitoring committee recommended that a Phase 3 trial of the investigational medicine be terminated due to insufficient efficacy. Shares of Esperion Therapeutics (ESPR), a drug company focused on developing and commercializing oral, low-density lipoprotein cholesterol lowering therapies, jumped 16% to $29 in pre-market trading following the announcement from Eli Lilly, whose shares remain halted.
08:01 EDTLLYLilly discontinuing development of evacetrapib for atherosclerotic heart disease
07:46 EDTLLYEli Lilly trading halted, news pending
Subscribe for More Information
05:08 EDTLLYEli Lilly expands strategic alliance with Innovent Biologics
Subscribe for More Information
October 9, 2015
16:01 EDTLLYEli Lilly acquires Phase 3 intranasal glucagon from Locemia Solutions
Subscribe for More Information
09:59 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:33 EDTLLYAmerican Society for Bone & Mineral Research to hold annual meeting
Subscribe for More Information
07:01 EDTLLYEli Lilly to add 30,000 square feet in R&D presence in New York
Subscribe for More Information
05:54 EDTLLYEli Lilly upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Vamil Divan upgraded Eli Lilly (LLY) to Outperform after his survey of 51 physicians suggested increasing use of the company's diabetes drug Jardiance. Jardiance is likely to drive near-term upside to Lilly while the company's pipeline is being underappreciated at current share levels, Divan tells investors in a research note. He raised his price target for shares to $105 from $89. The pharmaceutical giant closed yesterday down 24c to $83.75. The analyst also raised his sales estimates for Merck (MRK) and Johnson & Johnson (JNJ) following his physician survey.
October 8, 2015
07:05 EDTLLYEli Lilly's breast cancer candidate receives Breakthrough Therapy Designation
Subscribe for More Information
06:32 EDTLLYPiper Jaffray explains why drug prices are justifiable
Piper Jaffray's team of Biopharma analysts, led by Joshua Schimmer, explain this morning in research note to investors why they believe drug prices are justifiable. The "fairly lopsided" drug-pricing discussion "noise" has created attractive entry points for stocks in the sector, the analysts argue. They say that after adjusting for actual inflation, the growth of drug prices "does not seem particularly concerning." The current dialogue on the topic under-emphasizes the need to provide "extremely attractive incentives" for companies to embark on the "highly risky, capital-intensive, long-development cycle drug development path which is needed to bring new cures for important diseases," the analysts contend. Schimmer's top picks are Alexion (ALXN), Celgene (CELG) and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC) and Ignyta (RXDX) in the small-cap sector.
October 6, 2015
13:32 EDTLLYBiotechs plummet with TPP seen as industry negative
Biotechs are falling intraday after reports that the Trans-Pacific Partnership, or TPP, has language that the exclusivity period for bioligics, or drugs derived from a biological sources, would be eight years, less than the twelve years it is currently in the United States. WHAT'S NOTABLE: In the U.S., biologics are protected from competition by follow-on products for twelve years from the time they are first granted marketing approval by the U.S. Food and Drug Administration, a protection that is distinct from patent protection. Recent reports on the TPP suggest that the protection will last five years with an additional safety monitoring period of up to three years before a biosimilar can be registered, which would effectively be an eight year exclusivity period. ANALYST REACTION: Piper Jaffray analyst Joshua Schimmer, however, said the development is a "step forward," especially since it does not overrule the 12 years' exclusivity for the drugs in the U.S. While the sector asked for twelve years' exclusivity to match the U.S., eight years is a "reasonable compromise," the analyst argued. His top picks were Alexion (ALXN), Celgene (CELG), and Amgen (AMGN) in the large-cap space, GW Pharmaceuticals (GWPH) and bluebird bio (BLUE) among mid-caps, and Flex Pharma (FLKS), Lion Biotechnologies (LBIO), Otonomy (OTIC), and Ignyta (RXDX) in the small-cap sector. Further, Schimmer stated that more names look "increasingly compelling" amid the selloff. NOTABLE DECLINERS: Alexion is lower by 2.53%, Celgene is down 4.32%, Amgen is declining 1.91%, Biogen (BIIB) is down 3.4%, and Gilead Sciences (GILD) is falling 2.22%. STOCKS TO WATCH: Other publicly traded companies in the pharmaceutical space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
05:23 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro
Subscribe for More Information
October 1, 2015
10:37 EDTLLYBofA/Merrill's Top 10 US Ideas for Q4 2015
Subscribe for More Information
September 30, 2015
06:16 EDTLLYEli Lilly volatility at 52-week highs
Subscribe for More Information
05:41 EDTLLYEli Lilly, Adocia initiate new Phase 1b study evaluating BioChaperone Lispro
Subscribe for More Information
September 29, 2015
09:27 EDTLLYOn The Fly: Pre-market Movers
HIGHER: Yahoo (YHOO), up 4.5% after the company's board authorized the company to continue to pursue its spin-off of Aabaco Holdings, a newly formed independent registered investment company that will hold all of Yahoo's remaining holdings in Alibaba Group (BABA)... Phoenix Companies (PNX), up 164% after Nassau Reinsurance agreed to acquire Phoenix for $37.50 per share in cash... McDonald's (MCD), up 1.4% after the stock was upgraded to Outperform at Credit Suisse... Johnson & Johnson (JNJ), up 1% following upgrade at Deutsche Bank. LOWER: Esperion (ESPR), down 29% after reporting that the FDA has encouraged the company to initiate a cardiovascular outcomes trial promptly since any concern regarding the benefit/risk assessment of ETC-1002 could necessitate a completed cardiovascular outcomes trial before approval... Solera (SLH), down 2% after IHS (IHS) said on its earnings call that it is not pursuing an acquisition of the company, as previouly indicated in media reports... Zosano (ZSAN), down 54% after the company announced that it would discontinue its ZP-PTH agreement with Eli Lilly (LLY).
08:43 EDTLLYZosano Pharma price target lowered to $11 from $20 at Roth Capital
Roth Capital cut its price target on Zosano (ZSAN) after the company announced that it would discontinue its ZP-PTH agreement with Eli Lilly (LLY) in order to focus on a one time per week program. The firm expects Zosano's shares to drop significantly today, but it continues to expect the company's other programs to generate positive data. It keeps a Buy rating on the shares.
06:47 EDTLLYEli Lilly and Incyte's baricitinib Phase 3 study met primary objective
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use